6 results on '"Carletti Fabrizio"'
Number of results to display per page
Search Results
2. Rapid and qualitative identification of SARS-CoV-2 mutationsassociated with variants of concern using a multiplex RT-PCR assaycoupled with melting analysis
- Author
-
Sberna, Giuseppe, Fabeni, Lavinia, Berno, Giulia, Carletti, Fabrizio, Specchiarello, Eliana, Colavita, Francesca, Meschi, Silvia, Matusali, Giulia, Garbuglia, Anna Rosa, Bordi, Licia, and Lalle, Eleonora
- Subjects
Microbiology (medical) ,COVID-19 Testing ,Infectious Diseases ,Reverse Transcriptase Polymerase Chain Reaction ,SARS-CoV-2 ,Mutation ,COVID-19 ,Humans ,RNA, Viral ,General Medicine ,Retrospective Studies - Abstract
Considering the spread of new genetic variants and their impact on public health, it is important to have assays that are able to rapidly detect SARS-CoV-2 variants.We retrospectively examined 118 positive nasopharyngeal swabs, first characterized by the Sanger sequencing, using the Simplexa® SARS-CoV-2 Variants Direct assay, with the aim of evaluating the performance of the assay to detect N501Y, G496S, Q498R, Y505H, E484K, E484Q, E484A, and L452R mutations.A total of 111/118 nasopharyngeal swabs were in complete agreement with the Sanger sequencing, whereas the remaining seven samples were not amplified due to the low viral load. The evaluation of the ability of the assay to detect the E484Q mutation was performed using a viral isolate of the SARS-CoV-2 Kappa variant, showing concordance in 15/15 samples. Simplexa® SARS-CoV-2 Variant Direct assay was able to detect mutation pattern of Alpha, Beta, Gamma, Delta, and Omicron variants with 100% specificity and 94% sensitivity, whereas 100% sensitivity and specificity for the Kappa variant was observed.The assay can be useful to obtain faster results, contributing to a prompt surveillance of SARS-CoV-2 variants; however, it requires to be confirmed by the Sanger method, especially in the case of pattern of mutations that are different from those expected and also requires updates as new variants emerge.
- Published
- 2022
- Full Text
- View/download PDF
3. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
- Author
-
Tempestilli, Massimo, Caputi, Priscilla, Avataneo, Valeria, Notari, Stefania, Forini, Olindo, Scorzolini, Laura, Marchioni, Luisa, Ascoli Bartoli, Tommaso, Castilletti, Concetta, Lalle, Eleonora, Capobianchi, Maria R, Nicastri, Emanuele, D’Avolio, Antonio, Ippolito, Giuseppe, Agrati, Chiara, Abbonizio, Maria Alessandra, Albarello, Fabrizio, Amadei, Gioia, Amendola, Alessandra, Antinori, Andrea, Antonini, Mario, Barbaro, Raffaella, Bartolini, Barbara, Benigni, Martina, Bevilacqua, Nazario, Bordi, Licia, Bordoni, Veronica, Branca, Marta, Campioni, Paolo, Capobianchi, Maria Rosaria, Caporale, Cinzia, Caravella, Ilaria, Carletti, Fabrizio, Casetti, Rita, Chiappini, Roberta, Ciaralli, Carmine, Cimini, Eleonora, Colavita, Francesca, Corpolongo, Angela, Cristofaro, Massimo, Curiale, Salvatore, D’Abramo, Alessandra, Dantimi, Cristina, De Angelis, Alessia, De Angelis, Giada, Di Lorenzo, Rachele, Di Stefano, Federica, D’Offizi, Gianpiero, Ferraro, Federica, Fiorentini, Lorena, Frustaci, Andrea, Gallì, Paola, Garotto, Gabriele, Giancola, Maria Letizia, Giansante, Filippo, Giombini, Emanuela, Grassi, Germana, Greci, Maria Cristina, Lanini, Simone, Lapa, Daniele, Lepore, Luciana, Lucia, Andrea, Lufrani, Franco, Macchione, Manuela, Marani, Alessandra, Mariano, Andrea, Marini, Maria Cristina, Maritti, Micaela, Matusali, Giulia, Meschi, Silvia, Messina, Francesco, Montaldo, Chiara, Murachelli, Silvia, Noto, Roberto, Palazzolo, Claudia, Pallini, Emanuele, Palmieri, Fabrizio, Passeri, Virgilio, Pelliccioni, Federico, Petrecchia, Antonella, Petrone, Ada, Petrosillo, Nicola, Pianura, Elisa, Pisciotta, Maria, Pittalis, Silvia, Proietti, Costanza, Puro, Vincenzo, Rinonapoli, Gabriele, Rueca, Martina, Sacchi, Alessandra, Sanasi, Francesco, Santagata, Carmen, Scarcia, Silvana, Schininà, Vincenzo, Scognamiglio, Paola, Stazi, Giulia, Vaia, Francesco, Vairo, Francesco, and Valli, Maria Beatrice
- Subjects
0301 basic medicine ,Drug ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,COVID19 ,media_common.quotation_subject ,Critical Illness ,030106 microbiology ,Pneumonia, Viral ,remdesivir ,Loading dose ,Gastroenterology ,Antiviral Agents ,NO ,03 medical and health sciences ,Betacoronavirus ,Adenosine Triphosphate ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Pandemics ,media_common ,EC50 ,Original Research ,Aged ,Pharmacology ,Lung ,Alanine ,Nucleoside analogue ,business.industry ,SARS-CoV-2 ,COVID-19 ,Recovery of Function ,Prodrug ,Adenosine Monophosphate ,030104 developmental biology ,medicine.anatomical_structure ,Infectious Diseases ,Pharmacokinetics, COVID19, remdesivir ,Female ,business ,Coronavirus Infections ,medicine.drug - Abstract
Background Remdesivir is a prodrug of the nucleoside analogue GS-441524 and is under evaluation for treatment of SARS-CoV-2-infected patients. Objectives To evaluate the pharmacokinetics of remdesivir and GS-441524 in plasma, bronchoalveolar aspirate (BAS) and CSF in two critically ill COVID-19 patients. Methods Remdesivir was administered at 200 mg loading dose on the first day followed by 12 days of 100 mg in two critically ill patients. Blood samples were collected immediately after (C0) and at 1 (C1) and 24 h (C24) after intravenous administration on day 3 until day 9. BAS samples were collected on Days 4, 7 and 9 from both patients while one CSF on Day 7 was obtained in one patient. Remdesivir and GS-441524 concentrations were measured in these samples using a validated UHPLC-MS/MS method. Results We observed higher concentrations of remdesivir at C0 (6- to 7-fold higher than EC50 from in vitro studies) and a notable decay at C1. GS-441524 plasma concentrations reached a peak at C1 and persisted until the next administration. Higher concentrations of GS-441524 were observed in the patient with mild renal dysfunction. Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively. The CSF concentration found in Patient 2 was 25.7% with respect to plasma. GS-441524 levels in lung and CNS suggest compartmental differences in drug exposure. Conclusions We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients. Further study of the pharmacokinetic profile of remdesivir, GS-441524 and the intracellular triphosphate form are required.
- Published
- 2020
- Full Text
- View/download PDF
4. Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert Laboratory Network and the Chikungunya outbreak, Thailand, 2019
- Author
-
Venturi, Giulietta, Aberle, Stephan W, Avšič-Županc, Tatjana, Barzon, Luisa, Batejat, Christoph, Burdino, Elisa, Carletti, Fabrizio, Charrel, Rémi, Christova, Iva, Connell, Jeff, Corman, Victor Max, Emmanouil, Mary, Jääskeläinen, Anne J, Kurolt, Ivan, Lustig, Yaniv, Martinez, Miguel J, Koopmans, Marion, Nagy, Orsolya, Nguyen, Trung, Papa, Anna, Pérez-Ruiz, Mercedes, Pfeffer, Martin, Protic, Jelena, Reimerink, Johan, Rossini, Giada, Sánchez-Seco Fariñas, María Paz, Schmidt-Chanasit, Jonas, Söderholm, Sandra, Sudre, Bertrand, Van Esbroeck, Marjan, and Reusken, Chantal B
- Subjects
EVD-LabNet ,chikungunya ,lab surveillance ,Thailand ,lab preparedness and response ,travel - Published
- 2020
5. Cat-to-Human Orthopoxvirus Transmission, Northeastern Italy
- Author
-
Carletti, Fabrizio, Bordi, Licia, Castilletti, Concetta, Di Caro, Antonino, Falasca, Laura, Gioia, Cristiana, Ippolito, Giuseppe, Zaniratti, Stefania, Beltrame, Anna, Viale, Pierluigi, and Capobianchi, Maria Rosaria
- Subjects
letter ,human infection ,Orthopoxvirus ,zoonosis ,Letters to the Editor - Published
- 2009
6. Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics
- Author
-
Colavita, Francesca, Lapa, Daniele, Carletti, Fabrizio, Lalle, Eleonora, Messina, Francesco, Rueca, Martina, Matusali, Giulia, Meschi, Silvia, Bordi, Licia, Marsella, Patrizia, Nicastri, Emanuele, Marchioni, Luisa, Mariano, Andrea, Scorzolini, Laura, Ascoli Bartoli, Tommaso, Di Caro, Antonino, Ippolito, Giuseppe, Capobianchi, Maria Rosaria, Castilletti, Concetta, Abbate, Isabella, Agrati, Chiara, Aleo, Loredana, Alonzi, Tonino, Amendola, Alessandra, Apollonio, Claudia, Arduini, Nicolina, Bartolini, Barbara, Berno, Giulia, Biancone, Silvia, Biava, Mirella, Bibbò, Angela, Brega, Carla, Canali, Marco, Cannas, Angela, Carrara, Stefania, Casetti, Rita, Chiappini, Roberta, Ciafrone, Lucia, Cimini, Eleonora, Coen, Sabrina, Condello, Rossella, Coppola, Antonio, D’Arezzo, Silvia, Di Filippo, Stefania, Di Giuli, Chiara, Fabeni, Lavinia, Felici, Luisa, Ferraioli, Valeria, Forbici, Federica, Garbuglia, Anna Rosa, Giombini, Emanuela, Gori, Caterina, Graziano, Silvia, Gruber, Cesare Ernesto Maria, Khouri, Daniele, Leone, Barbara, Massimino, Chiara, Mazzarelli, Antonio, Minosse, Claudia, Montaldo, Claudia, Neri, Stefania, Nisii, Carla, Petrivelli, Elisabetta, Petroni, Fabrizio, Petruccioli, Elisa, Pisciotta, Marina, Pizzi, Daniele, Prota, Gianluca, Raparelli, Fabrizio, Rozera, Gabriella, Sabatini, Rossella, Sarti, Silvia, Sberna, Giuseppe, Sciamanna, Roberta, Selleri, Marina, Selvaggi, Carla, Sias, Catia, Stellitano, Chiara, Toffoletti, Antonietta, Truffa, Silvia, Turchi, Federica, Valli, Maria Beatrice, Venditti, Carolina, Vescovo, Tiziana, Vincenti, Donatella, Vulcano, Antonella, Zambelli, Emma, Abbonizio, Maria Alessandra, Albarello, Fabrizio, Amadei, Gioia, Antonini, Mario, Barbaro, Raffaella, Benigni, Martina, Bevilacqua, Nazario, Bordoni, Veronica, Branca, Marta, Campioni, Paolo, Caporale, Cinzia, Caravella, Ilaria, Ciaralli, Carmine, Corpolongo, Angela, Cristofaro, Massimo, Curiale, Salvatore, D’Abramo, Alessandra, Dantimi, Cristina, De Angelis, Alessia, De Angelis, Giada, Di Lorenzo, Rachele, Di Stefano, Federica, Ferraro, Federica, Fiorentini, Lorena, Frustaci, Andrea, Gallì, Paola, Garotto, Gabriele, Giancola, Maria Letizia, Giansante, Filippo, Greci, Maria Cristina, Lanini, Simone, Lepore, Luciana, Lucia, Andrea, Lufrani, Franco, Macchione, Manuela, Marani, Alessandra, Marini, Maria Cristina, Maritti, Micaela, Montaldo, Chiara, Murachelli, Silvia, Noto, Roberto, Palazzolo, Claudia, Pallini, Emanuele, Passeri, Virgilio, Pelliccioni, Federico, Petrecchia, Antonella, Petrone, Ada, Petrosillo, Nicola, Pianura, Elisa, Pisciotta, Maria, Pittalis, Silvia, Proietti, Costanza, Puro, Vincenzo, Rinonapoli, Gabriele, Sacchi, Alessandra, Sanasi, Francesco, Santagata, Carmen, Scarcia, Silvana, Schininà, Vincenzo, Scognamiglio, Paola, Stazi, Giulia, Vaia, Francesco, and Vairo, Francesco
- Subjects
0301 basic medicine ,Immunoglobulin A ,Immunoglobulin G ,Virus ,NO ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Major Article ,SARS-cov-2 ,Medicine ,030212 general & internal medicine ,Viral shedding ,Neutralizing antibody ,Phylogenesis ,biology ,Viral culture ,business.industry ,Antibody response ,COVID-19 ,Italy ,Virus shedding ,3. Good health ,AcademicSubjects/MED00290 ,030104 developmental biology ,Infectious Diseases ,Oncology ,Immunoglobulin M ,Immunology ,biology.protein ,business - Abstract
Background The pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains unclear. We report the detection of viral RNA from different anatomical districts and the antibody profile in the first 2 COVID-19 cases diagnosed in Italy. Methods We tested for SARS-CoV-2 RNA clinical samples, either respiratory and nonrespiratory (ie, saliva, serum, urine, vomit, rectal, ocular, cutaneous, and cervico-vaginal swabs), longitudinally collected from both patients throughout the hospitalization. Serological analysis was carried out on serial serum samples to evaluate IgM, IgA, IgG, and neutralizing antibody levels. Results SARS-CoV-2 RNA was detected since the early phase of illness, lasting over 2 weeks in both upper and lower respiratory tract samples. Virus isolate was obtained from acute respiratory samples, while no infectious virus was rescued from late respiratory samples with low viral RNA load, collected when serum antibodies had been developed. Several other specimens came back positive, including saliva, vomit, rectal, cutaneous, cervico-vaginal, and ocular swabs. IgM, IgA, and IgG were detected within the first week of diagnosis, with IgG appearing earlier and at higher titers. Neutralizing antibodies developed during the second week, reaching high titers 32 days after diagnosis. Conclusions Our longitudinal analysis showed that SARS-CoV-2 RNA can be detected in different body samples, which may be associated with broad tropism and different spectra of clinical manifestations and modes of transmission. Profiling antibody response and neutralizing activity can assist in laboratory diagnosis and surveillance actions.
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.